TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis

Infliximab in inflammatory bowel disease

(2019) Konstantinos Papamichael et al.   Therapeutic Advances in Chronic Disease

Update upon the infection risk in patients receiving TNF alpha inhibitors

(2019) Giuseppe Murdaca et al.   Expert Opinion On Drug Safety

The pathogenesis of psoriatic arthritis

(2018) Douglas J Veale et al.   LANCET

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

(2018) Atul Deodhar et al.   LANCET

Role of comorbidities in spondyloarthritis including psoriatic arthritis

(2018) Silvia Scriffignano et al.   CLINICAL RHEUMATOLOGY

Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)

(2018) Sara Rundquist et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

(2018) Jasvinder A. Singh et al.   Arthritis & Rheumatology

Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis

(2017) Giuseppe Murdaca et al.   Expert Opinion On Drug Safety

Adalimumab for the treatment of uveitis

(2017) Kara C. LaMattina et al.   Expert Review of Clinical Immunology

Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort

(2017) Ennio Lubrano et al.   JOURNAL OF RHEUMATOLOGY

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

(2017) Peter Nash et al.   LANCET

Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases

(2017) Michael Croft et al.   Nature Reviews Rheumatology

Psoriatic Arthritis

(2017) Christopher T. Ritchlin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

(2017) Philip Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

(2017) Dafna Gladman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor necrosis factor inhibitors in psoriatic arthritis

(2017) Santhi Mantravadi et al.   Expert Review of Clinical Pharmacology

Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics

(2016) Francine Chingcuanco et al.   ANNALS OF INTERNAL MEDICINE

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2016) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis

(2016) Patompong Ungprasert et al.   CLINICAL RHEUMATOLOGY

Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA

(2016) Aoibhlinn O’Toole et al.   DIGESTIVE DISEASES AND SCIENCES

Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis

(2016) Ennio Lubrano et al.   DRUGS

Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis

(2016) Stefanos Bonovas et al.   Expert Opinion On Drug Safety

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

(2016) M. Cutolo et al.   JOURNAL OF RHEUMATOLOGY

Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors

(2016) E. Lubrano et al.   JOURNAL OF RHEUMATOLOGY

Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study

(2016) Fabio Massimo Perrotta et al.   POSTGRADUATE MEDICINE

Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis

(2016) Patompong Ungprasert et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network

(2016) Hélène Vallet et al.   Arthritis & Rheumatology

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

(2015) L Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score

(2015) Monika M Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis

(2015) Sarah S. Thomas et al.   BIODRUGS

Infection risk associated with anti-TNF-α agents: a review

(2015) Giuseppe Murdaca et al.   Expert Opinion On Drug Safety

Certolizumab pegol for the treatment of psoriatic arthritis

(2015) Renata Baronaite Hansen et al.   Expert Review of Clinical Immunology

Adalimumab markedly improves enthesitis in patients with psoriatic arthritis: Evaluation with a magnetic resonance imaging scoring system

(2015) Koichi Yanaba et al.   JOURNAL OF DERMATOLOGY

Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study

(2015) Laura C. Coates et al.   JOURNAL OF RHEUMATOLOGY

Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs

(2015) Fabio Massimo Perrotta et al.   JOURNAL OF RHEUMATOLOGY

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Minimal Disease Activity and Anti-Tumor Necrosis Factor Therapy in Psoriatic Arthritis

(2015) Amir Haddad et al.   ARTHRITIS CARE & RESEARCH

Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study

(2014) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease

(2014) Ignazio Olivieri et al.   AUTOIMMUNITY REVIEWS

TNF-α Gene Polymorphisms: Association with Disease Susceptibility and Response to Anti-TNF-α Treatment in Psoriatic Arthritis

(2014) Giuseppe Murdaca et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Updated Guidelines for the Management of Axial Disease in Psoriatic Arthritis

(2014) P. Nash et al.   JOURNAL OF RHEUMATOLOGY

Composite Disease Activity and Responder Indices for Psoriatic Arthritis: A Report from the GRAPPA 2013 Meeting on Development of Cutoffs for Both Disease Activity States and Response

(2014) P. S. Helliwell et al.   JOURNAL OF RHEUMATOLOGY

Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis

(2014) Philip Helliwell et al.   ARTHRITIS CARE & RESEARCH

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

(2013) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study

(2013) D. Gladman et al.   ARTHRITIS CARE & RESEARCH

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

(2012) Philip S Helliwell et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of Ustekinumab With Other Biological Agents for the Treatment of Moderate to Severe Plaque Psoriasis

(2012) Vincent W. Lin et al.   ARCHIVES OF DERMATOLOGY

Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment

(2012) Georg Schett et al.   Nature Reviews Rheumatology

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

(2011) Zoe Ash et al.   ANNALS OF THE RHEUMATIC DISEASES

Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey

(2011) B. B. Aggarwal et al.   BLOOD

Differential Features Between Primary Ankylosing Spondylitis and Spondylitis Associated with Psoriasis and Inflammatory Bowel Disease

(2011) R. PEREZ ALAMINO et al.   JOURNAL OF RHEUMATOLOGY

Beyond Early Diagnosis: Occult Psoriatic Arthritis

(2010) C. PALAZZI et al.   JOURNAL OF RHEUMATOLOGY

Responses to Adalimumab in Patients with Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-label Study

(2010) D. D. GLADMAN et al.   JOURNAL OF RHEUMATOLOGY

Patient-reported Outcomes in a Randomized Trial of Etanercept in Psoriatic Arthritis

(2010) P. J. MEASE et al.   JOURNAL OF RHEUMATOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data

(2010) Laura C. Coates et al.   ARTHRITIS CARE & RESEARCH

Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment

(2009) L C Coates et al.   ANNALS OF THE RHEUMATIC DISEASES

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions

(2009) F Van den Bosch et al.   ANNALS OF THE RHEUMATIC DISEASES

International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis

(2009) Vinod Chandran et al.   ARTHRITIS AND RHEUMATISM

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

(2009) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

(2008) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Do TNF-blockers reduce or induce uveitis?

(2008) T. Cobo-Ibanez et al.   RHEUMATOLOGY

TNF-mediated inflammatory disease

(2007) JR Bradley   JOURNAL OF PATHOLOGY

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS